Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms

Tariq I. Mughal, Omar Abdel-Wahab, Raajit Rampal, Ruben Mesa, Steffen Koschmieder, Ross Levine, Rüdiger Hehlmann, Giuseppe Saglio, Tiziano Barbui, Richard A. Van Etten

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

This review is based on the deliberations at the 5th John Goldman Colloquium held in Estoril on 2nd October 2015 and the 9th post-ASH International Workshop on chronic myeloid leukemia (CML) and BCR-ABL1-negative myeloproliferative neoplasms (MPN) which took place on the 10th–11th December 2014, immediately following the 56th American Society of Hematology Annual Meeting. It has been updated since and summarizes the most recent advances in the biology and therapy of these diseases, in particular updates of genetics of MPN, novel insights from mouse MPN models, targeting CML stem cells and its niche; clinical advances include updates on JAK2 inhibitors and other therapeutic approaches to BCR-ABL1-negative MPNs, the use of alpha interferons, updates on tyrosine kinase inhibitors (TKI) randomized trials in CML, TKI cessation studies, and optimal monitoring strategies.

Original languageEnglish (US)
Pages (from-to)1517-1526
Number of pages10
JournalLeukemia and Lymphoma
Volume57
Issue number7
DOIs
StatePublished - Jul 2 2016

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Stem Cell Niche
Myeloid Progenitor Cells
Neoplasms
Interferon-alpha
Education
Therapeutics

Keywords

  • Molecular genetics
  • myeloid leukemias and dysplasias
  • stem and primitive progenitor cells

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Mughal, T. I., Abdel-Wahab, O., Rampal, R., Mesa, R., Koschmieder, S., Levine, R., ... Van Etten, R. A. (2016). Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms. Leukemia and Lymphoma, 57(7), 1517-1526. https://doi.org/10.1080/10428194.2016.1185783

Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms. / Mughal, Tariq I.; Abdel-Wahab, Omar; Rampal, Raajit; Mesa, Ruben; Koschmieder, Steffen; Levine, Ross; Hehlmann, Rüdiger; Saglio, Giuseppe; Barbui, Tiziano; Van Etten, Richard A.

In: Leukemia and Lymphoma, Vol. 57, No. 7, 02.07.2016, p. 1517-1526.

Research output: Contribution to journalReview article

Mughal, TI, Abdel-Wahab, O, Rampal, R, Mesa, R, Koschmieder, S, Levine, R, Hehlmann, R, Saglio, G, Barbui, T & Van Etten, RA 2016, 'Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms', Leukemia and Lymphoma, vol. 57, no. 7, pp. 1517-1526. https://doi.org/10.1080/10428194.2016.1185783
Mughal, Tariq I. ; Abdel-Wahab, Omar ; Rampal, Raajit ; Mesa, Ruben ; Koschmieder, Steffen ; Levine, Ross ; Hehlmann, Rüdiger ; Saglio, Giuseppe ; Barbui, Tiziano ; Van Etten, Richard A. / Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms. In: Leukemia and Lymphoma. 2016 ; Vol. 57, No. 7. pp. 1517-1526.
@article{6b8ce1387e7b4079a45df10faa3bf686,
title = "Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms",
abstract = "This review is based on the deliberations at the 5th John Goldman Colloquium held in Estoril on 2nd October 2015 and the 9th post-ASH International Workshop on chronic myeloid leukemia (CML) and BCR-ABL1-negative myeloproliferative neoplasms (MPN) which took place on the 10th–11th December 2014, immediately following the 56th American Society of Hematology Annual Meeting. It has been updated since and summarizes the most recent advances in the biology and therapy of these diseases, in particular updates of genetics of MPN, novel insights from mouse MPN models, targeting CML stem cells and its niche; clinical advances include updates on JAK2 inhibitors and other therapeutic approaches to BCR-ABL1-negative MPNs, the use of alpha interferons, updates on tyrosine kinase inhibitors (TKI) randomized trials in CML, TKI cessation studies, and optimal monitoring strategies.",
keywords = "Molecular genetics, myeloid leukemias and dysplasias, stem and primitive progenitor cells",
author = "Mughal, {Tariq I.} and Omar Abdel-Wahab and Raajit Rampal and Ruben Mesa and Steffen Koschmieder and Ross Levine and R{\"u}diger Hehlmann and Giuseppe Saglio and Tiziano Barbui and {Van Etten}, {Richard A.}",
year = "2016",
month = "7",
day = "2",
doi = "10.1080/10428194.2016.1185783",
language = "English (US)",
volume = "57",
pages = "1517--1526",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms

AU - Mughal, Tariq I.

AU - Abdel-Wahab, Omar

AU - Rampal, Raajit

AU - Mesa, Ruben

AU - Koschmieder, Steffen

AU - Levine, Ross

AU - Hehlmann, Rüdiger

AU - Saglio, Giuseppe

AU - Barbui, Tiziano

AU - Van Etten, Richard A.

PY - 2016/7/2

Y1 - 2016/7/2

N2 - This review is based on the deliberations at the 5th John Goldman Colloquium held in Estoril on 2nd October 2015 and the 9th post-ASH International Workshop on chronic myeloid leukemia (CML) and BCR-ABL1-negative myeloproliferative neoplasms (MPN) which took place on the 10th–11th December 2014, immediately following the 56th American Society of Hematology Annual Meeting. It has been updated since and summarizes the most recent advances in the biology and therapy of these diseases, in particular updates of genetics of MPN, novel insights from mouse MPN models, targeting CML stem cells and its niche; clinical advances include updates on JAK2 inhibitors and other therapeutic approaches to BCR-ABL1-negative MPNs, the use of alpha interferons, updates on tyrosine kinase inhibitors (TKI) randomized trials in CML, TKI cessation studies, and optimal monitoring strategies.

AB - This review is based on the deliberations at the 5th John Goldman Colloquium held in Estoril on 2nd October 2015 and the 9th post-ASH International Workshop on chronic myeloid leukemia (CML) and BCR-ABL1-negative myeloproliferative neoplasms (MPN) which took place on the 10th–11th December 2014, immediately following the 56th American Society of Hematology Annual Meeting. It has been updated since and summarizes the most recent advances in the biology and therapy of these diseases, in particular updates of genetics of MPN, novel insights from mouse MPN models, targeting CML stem cells and its niche; clinical advances include updates on JAK2 inhibitors and other therapeutic approaches to BCR-ABL1-negative MPNs, the use of alpha interferons, updates on tyrosine kinase inhibitors (TKI) randomized trials in CML, TKI cessation studies, and optimal monitoring strategies.

KW - Molecular genetics

KW - myeloid leukemias and dysplasias

KW - stem and primitive progenitor cells

UR - http://www.scopus.com/inward/record.url?scp=84975248782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975248782&partnerID=8YFLogxK

U2 - 10.1080/10428194.2016.1185783

DO - 10.1080/10428194.2016.1185783

M3 - Review article

C2 - 27240645

AN - SCOPUS:84975248782

VL - 57

SP - 1517

EP - 1526

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 7

ER -